News | October 22, 2006

Discrepancy Found in Use of Standard Tests to Diagnose Lung vs. Cardiac Disease

Chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF) are two of the most common medical reasons for hospitalization among middle-aged and older patients. Both have accepted standards for diagnosis and management, supported by large bodies of scientific evidence and international practice guidelines; yet a new study from Boston’s Caritas St Elizabeth’s Medical Center, published in the October issue of Respiratory Care, shows that the use of the primary confirmatory tests—recommended both for diagnosis and assessment of severity—differs substantially in the two diseases.     

According to guidelines such as those of the Global Initiative for Obstructive Lung Disease (, diagnosing COPD and choosing appropriate therapy based on disease severity relies on spirometry, a simple test in which lung capacity and how fast air can be expelled from the lungs are measured noninvasively in a doctor’s office or laboratory. 

The new study, by Mahendra Demarla and colleagues, shows that only about one-third of patients admitted to the hospital with the diagnosis of “COPD” during a recent 6-month period had had spirometry performed either in the hospital or during the preceding 8 years. This means that the majority of patients who required hospitalization for this common and life-threatening condition had not undergone the specific test required to confirm that this diagnosis was correct. 

Further, the investigators found that, of the patients who had undergone spirometry, in 10% of instances the findings were normal, indicating that the diagnosis of COPD was incorrect, and in another 19% it revealed a different functional pattern suggesting the presence of some other lung disease.

Related Content

FDA Clears Advancements for Viewray MRIdian Radiation Therapy System
Technology | Image Guided Radiation Therapy (IGRT) | February 21, 2019
February 21, 2019 — ViewRay Inc. received 510(k) clearance from the U.S.
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
Elekta Introduces Strategy for Precision Radiation Medicine at ASTRO 2018

Elekta SmartClinic is one of the key features in the Mosaiq Plaza suite of data-focused integrative oncology software

News | Radiation Therapy | October 30, 2018
At the American Society for Radiation Oncology (ASTRO) Annual Meeting, Oct. 21-24 in San Antonio, Elekta introduced the...
ViewRay and Miami Cancer Institute Host Symposium on MR-Guided Radiation Therapy
News | Image Guided Radiation Therapy (IGRT) | October 05, 2018
October 5, 2018 — Leading oncology experts from around the world recently met to discuss the integration of...
Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S